CRL vs SOLV — Key Metrics
| Metric | CRL (CHARLES RIVER LABORATORIES INTERNATIONAL INC) | SOLV (SOLVENTUM CORP) |
|---|---|---|
| Price | 333.25 | 86.48 |
| Market Cap | 15.97 Billion | 14.68 Billion |
| P/E (TTM) | 311.45 | 97.17 |
| P/B (Quarterly) | 4.845 | 3.08 |
| P/S (TTM) | 4.02 | 1.8 |
| Net Profit Margin (TTM) | 1.0 | 1.9 |
| Gross Margin (TTM) | 33.3 | 54.8 |
| ROE (TTM) | 1.3 | 3.2 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Greatly Underperform
Outperform
Recommendation Summary
Stock CRL is projected to greatly underperform the market, stock SOLV is projected to outperform the market. Upfront Recommendation: SOLV.
Financial Metrics
| CRL | Metrics | SOLV |
|---|---|---|
| $333.25 | Price | $86.48 |
| — | Market Capitalization | — |
| 311.45 | Price to Earnings Ratio | 97.17 |
| 4.02 | Price to Sales | 1.8 |
| 39.96 | Price to FCF Ratio | 47.65 |
| 12.05 | Price to Gross Profit | 3.28 |
| 10.4 | Price to Current Assets | 3.98 |
CRL vs SOLV at a glance
Charles River Laboratories International INC (CRL) and Solventum Corp (SOLV) are both in the Healthcare sector. They are similar in size: $16.0 billion and $14.7 billion in market value.
On trailing-twelve-month figures, CRL trades at 311.4 times trailing earnings and SOLV at 97.2; net profit margins are 1.0% and 1.9%.
The Upfront Investment model currently rates CRL Greatly Underperform and SOLV Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.